Von capito am 08.03.2018 im Senat eingereicht, ist deren epi vermeldet hat.
S. 2523
To amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, and for other purposes.
IN THE SENATE OF THE UNITED STATES
March 8, 2018
Mrs. Capito (for herself and Mr. Heinrich) introduced the following bill; which was read twice and referred to the Committee on Finance
A BILL
To amend title XVIII of the Social Security Act to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Colorectal Cancer Detection Act of 2018”.
SEC. 2. MEDICARE COVERAGE FOR FDA-APPROVED QUALIFYING COLORECTAL CANCER SCREENING BLOOD-BASED TESTS.
(a) In General.—Section 1861(pp) of the Social Security Act (42 U.S.C. 1395x(pp)) is amended—
(1) in paragraph (1)—
(A) by redesignating subparagraph (D) as subparagraph (E); and
(B) by inserting after subparagraph (C) the following new subparagraph:
“(D) Qualifying colorectal cancer screening blood-based test.”; and
(2) by adding at the end the following new paragraph:
“(3) The term ‘qualifying colorectal cancer screening blood-based test’ means, with respect to a year, a screening blood-based test for the early detection of colorectal cancer furnished in the year that was marketed or used, as applicable, in accordance with the relevant provisions of section 353 of the Public Health Service Act or the Federal Food, Drug, and Cosmetic Act more than 6 months before the beginning of the year.”.
(b) Frequency Limits For Colorectal Cancer Screening Tests And Payment Amount For Qualifying Colorectal Cancer Screening Blood-Based Tests.—Section 1834(d) of the Social Security Act (42 U.S.C. 1395m(d)) is amended—
(1) by amending clause (ii) of paragraph (1)(B) to read as follows:
“(ii) if the test is performed within—
“(I) the 11 months after a previous screening fecal-occult blood test or a previous qualifying colorectal cancer screening blood-based test;
Zurück
Weiter
